ReviewChinese medical journal pulmonary and critical care medicine2023
Targeting tumor microenvironment for non-small cell lung cancer immunotherapy.
Review in Chinese medical journal pulmonary and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Genomic signature driving preinvasive to invasive processes in stage I lung adenocarcinoma.International journal of cancer · 2026Article
- Efficacy and safety of chemotherapy alone or in combination with immune checkpoint inhibitors as the first-line treatment for patients with advanced HER2 -mutant non-small cell lung cancer: A multi-center retrospective study.Chinese medical journal · 2026Article
- Chemotherapy-free regimen: Real-world efficacy and safety of anlotinib plus PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Intratumoral immune-microbial crosstalk shaped by tumor cell-derived extracellular vesicles encapsulating berberine boosts lung cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Metabolic Checkpoints in CD8International journal of biological sciences · 2026Review
- An IHC-derived TLS-CD8-macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC.Frontiers in immunology · 2026Article
- Article
- H3K18 lactylation in cancer-associated fibroblasts drives malignant pleural effusion progression via TNFR2Experimental & molecular medicine · 2025Article
- Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers.Journal of surgical oncology · 2025Review
- Oncogenic driver mutations underlie the spatial tumour immune landscape of non-small cell lung cancer.Nature communications · 2025Article
- Characteristics of gut and lung microbiota in patients with lung masses and their relationship with clinical features.BMC microbiology · 2025Article
- Review
- Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials.Molecular pharmaceutics · 2025Review
- ATF3 Within the Interferon Signaling Pathway: A Potential Biomarker for Predicting Pathological Response to Neoadjuvant Chemoimmunotherapy.Thoracic cancer · 2025Article
- Multi-omics analyses reveal biological and clinical insights in recurrent stage I non-small cell lung cancer.Nature communications · 2025Article
- AXL: shapers of tumor progression and immunosuppressive microenvironments.Molecular cancer · 2025Review
- Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.Frontiers in immunology · 2025Review
- The CD300c antibody CL7 suppresses tumor growth by regulating the tumor microenvironment in non-small cell lung carcinoma.Frontiers in oncology · 2025Article
- Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion.Journal for immunotherapy of cancer · 2024Article
- Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect.Journal for immunotherapy of cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) is composed of different cellular and non-cellular elements. Constant interactions between tumor cells and the TME are responsible for tumor initiation, tumor progression, and responses to therapies. Immune cells in the TME can be classified into two broad categories, namely adaptive and innate immunity. Targeting these immune cells has attracted substantial research and clinical interest. Current research focuses on identifying key molecular players and developing targeted therapies. These approaches may offer more efficient ways of treating different cancers. In this review, we explore the heterogeneity of the TME in non-small cell lung cancer, summarize progress made in targeting the TME in preclinical and clinical studies, discuss the potential predictive value of the TME in immunotherapy, and highlight the promising effects of bispecific antibodies in the era of immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.